| Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04 MJ O'Connell, LH Colangelo, RW Beart, NJ Petrelli, CJ Allegra, S Sharif, ... Journal of clinical oncology 32 (18), 1927-1934, 2014 | 497 | 2014 |
| Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial CJ Allegra, G Yothers, MJ O’Connell, RW Beart, TF Wozniak, HC Pitot, ... Journal of the National Cancer Institute 107 (11), djv248, 2015 | 361 | 2015 |
| 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells SK Kulp, YT Yang, CC Hung, KF Chen, JP Lai, PH Tseng, JW Fowble, ... Cancer research 64 (4), 1444-1451, 2004 | 307 | 2004 |
| First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2− advanced breast cancer: tumor response and pain reduction in the phase 3 MONALEESA-2 trial W Janni, E Alba, T Bachelot, S Diab, M Gil-Gil, TJ Beck, L Ryvo, R Lopez, ... Breast Cancer Research and Treatment 169, 469-479, 2018 | 56 | 2018 |
| Panitumumab, gemcitabine, and carboplatin as treatment for women with metastatic triple-negative breast cancer: a Sarah Cannon Research Institute phase II trial DA Yardley, PJ Ward, BR Daniel, JF Eakle, RE Lamar, CM Lane, ... Clinical Breast Cancer 16 (5), 349-355, 2016 | 41 | 2016 |
| A randomized, double‐blinded, Phase II trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX‐427) in patients with previously untreated stage IV non‐squamous‐non … DR Spigel, DL Shipley, DM Waterhouse, SF Jones, PJ Ward, KC Shih, ... The Oncologist 24 (12), e1409-e1416, 2019 | 34 | 2019 |
| Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and … JA Samuel, JW Wilson, H Bandos, RM Elledge, A Robidoux, ... Cancer Research 75 (9_Supplement), S3-02-S3-02, 2015 | 34 | 2015 |
| A phase 1 study evaluating rovalpituzumab tesirine in frontline treatment of patients with extensive-stage SCLC CL Hann, TF Burns, A Dowlati, D Morgensztern, PJ Ward, MM Koch, ... Journal of Thoracic Oncology 16 (9), 1582-1588, 2021 | 32 | 2021 |
| Randomized phase II study of ramucirumab or icrucumab in combination with capecitabine in patients with previously treated locally advanced or metastatic breast cancer LT Vahdat, R Layman, DA Yardley, W Gradishar, MA Salkeni, AA Joy, ... The oncologist 22 (3), 245-254, 2017 | 23 | 2017 |
| Impact of anti-HER2 treatments combined with atezolizumab on the tumor immune microenvironment in early or metastatic breast cancer: results from a phase ib study EP Hamilton, V Kaklamani, C Falkson, GA Vidal, PJ Ward, M Patre, ... Clinical breast cancer 21 (6), 539-551, 2021 | 21 | 2021 |
| Phase II trial of ofatumumab (OFA) for older patients and patients who refuse fludarabine-based regimens with previously untreated chronic lymphocytic leukemia (CLL) or small … IW Flinn, WN Harwin, P Ward, HH Doss, SW Papish, JD Hainsworth, ... Blood 120 (21), 719, 2012 | 18 | 2012 |
| Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib RC Coombes, S Howell, SR Lord, L Kenny, J Mansi, Z Mitri, C Palmieri, ... Nature communications 14 (1), 4444, 2023 | 17 | 2023 |
| Efficacy and safety of ribociclib with letrozole in US patients enrolled in the MONALEESA-2 study DA Yardley, L Hart, A Favret, S Blau, S Diab, D Richards, J Sparano, ... Clinical breast cancer 19 (4), 268-277. e1, 2019 | 17 | 2019 |
| Cabazitaxel plus lapatinib as therapy for HER2+ metastatic breast cancer with intracranial metastases: results of a dose-finding study DA Yardley, LL Hart, PJ Ward, GL Wright, M Shastry, L Finney, ... Clinical breast cancer 18 (5), e781-e787, 2018 | 16 | 2018 |
| Xaluritamig, a STEAP1× CD3 XmAb 2+ 1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study WK Kelly, DC Danila, CC Lin, JL Lee, N Matsubara, PJ Ward, ... Cancer Discovery 14 (1), 76-89, 2024 | 15 | 2024 |
| A randomized phase II study of eribulin/cyclophosphamide or docetaxel/cyclophosphamide as neoadjuvant therapy in operable HER2-negative breast cancer DA Yardley, D Shipley, J Zubkus, GL Wright, PJ Ward, A Mani, M Shastry, ... Clinical breast cancer 19 (1), 1-9, 2019 | 14 | 2019 |
| SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer H Borghaei, F de Marinis, D Dumoulin, C Reynolds, W Theelen, ... Annals of Oncology 35 (1), 66-76, 2024 | 13 | 2024 |
| Abstract PD1-05: Atezolizumab in combination with trastuzumab emtansine or with trastuzumab and pertuzumab in patients with HER2-positive breast cancer and atezolizumab with … EP Hamilton, V Kaklamani, C Falkson, GA Vidal, PJ Ward, M Patre, ... Cancer Research 80 (4_Supplement), PD1-05-PD1-05, 2020 | 11 | 2020 |
| Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a … AMC Dingemans, K Syrigos, L Livi, A Paulus, SW Kim, Y Chen, E Felip, ... Journal Of Clinical Oncology 41 (17_suppl), LBA9016-LBA9016, 2023 | 10 | 2023 |
| Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial … CE Geyer Jr, H Bandos, P Rastogi, SA Jacobs, A Robidoux, ... Breast cancer research and treatment 193 (3), 555-564, 2022 | 8 | 2022 |
Stewart WolmarkStewart Wolmark is chairman of the National Surgical Adjuvant Breast Project and a professor of在 pcc.edu 的电子邮件经过验证
